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Cancer incidence varies markedly
among states because of population
heterogeneity regarding risk, genetic,
and demographic factors. Population-
based cancer registries are essential to
monitoring cancer trends and control.
The Centers for Disease Control
and Prevention and the North Ameri-
can Association of Central Cancer Reg-
istries, through the National Program
of Cancer Registries, are helping state
registries generate more and better data
nationwide. The National Program of
Cancer Registries has supported the
enhancement of 36 registries and the
creation of 13 new registries in 45 states,
3 territories, and the District of Colum-
bia, providing national standards for
completeness, timeliness, and qual-
ity; financial support; and technical
assistance. 
Users must be aware of diverse is-
sues that influence collection and inter-
pretation of cancer registry data, such
as multiple cancer diagnoses, duplicate
reports, reporting delays, misclassifica-
tion of race/ethnicity, and pitfalls in es-
timations of cancer incidence rates. At-
tention to these issues and intense use
of the available data for cancer surveil-
lance will enable maximum societal
benefit from the emerging network of
population-based state cancer reg-
istries. (Am J Public Health. 2000;90:
695–698)
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Population-based state cancer registries
collect, classify, consolidate, and link infor-
mation on new cancer cases from hospital re-
ports, medical records, pathology reports,
hospital discharge abstracts, and death certifi-
cates. Through a time- and resource-intensive
process,1 the registries generate data of vast
surveillance potential for identifying patterns
and trends in various population groups, in
different geographic areas, and over time; ori-
enting prevention efforts and health care plan-
ning; supporting epidemiologic, biomedical,
and health services research; and framing
public health policy.2–8 Patterns of cancer inci-
dence and mortality vary markedly between
and within states and regions in the United
States9–11 and across countries,12 reflecting
population heterogeneity in regard to demo-
graphic and genetic composition as well as
exposure to environmental and behavioral risk
factors.13–16 Thus, a national system of popu-
lation-based cancer registries is essential to
monitor state- and local-level cancer patterns
and trends and to orient cancer prevention and
control activities.8
Despite the importance of local cancer
data in developing and evaluating control
measures, 10 states had no cancer registry in
1990, and many existing ones lacked finan-
cial or technical resources to collect complete,
accurate, and timely data of requisite quality.
In 1992, Congress passed the Cancer Reg-
istries Amendment Act (Pub L 102-515), es-
tablishing the National Program of Cancer
Registries. This legislation authorized the
Centers for Disease Control and Prevention
(CDC) to provide funds to states and territo-
ries to improve existing cancer registries; plan
and implement new registries; develop model
legislation and regulations for states to en-
hance the viability of registry operations; set
standards for data completeness, timeliness,
and quality; provide training for registry per-
sonnel; and help establish a computerized re-
porting system.17 To ensure complete and
timely reporting in each state, the federal
statute requires state-specific laws authorizing
the cancer registry along with 8 categories of
regulations intended to (1) require mandatory
reporting of newly diagnosed cancer cases by
hospitals and other health care facilities, (2)
require reporting of cancer cases by physi-
cians and other practitioners, (3) guarantee ac-
cess by the state cancer registry to all medical
records of persons with cancer, (4) require use
of standardized reporting formats, (5) ensure
confidentiality of cancer case data, (6) allow
use of confidential data by researchers, (7) au-
thorize studies using cancer registry data, and
(8) protect persons complying with the law
from liability.18
When the CDC created the National Pro-
gram of Cancer Registries, 37 states had laws
authorizing state cancer registries, 14 had all
enabling regulations in place, and only 9—
California, Indiana, Minnesota, New Jersey,
New York, Ohio, Rhode Island, Vermont, and
Washington—had both components.18 During
1997, the program expanded by adding 6 reg-
istries (Connecticut, Delaware, Tennessee,
Puerto Rico, Virgin Islands, and Republic of
Palau), increasing the number of supported
registries to 49 (45 in states, 3 in territories,
and 1 in the District of Columbia).17 By 1999,
45 states and the District of Columbia had au-
thorizing legislation, and 39 states had en-
abling regulations.
The CDC set national standards for
completeness (95% unduplicated malignant
cases), timeliness (reports within 6 months of
diagnosis), and quality19 and, in fiscal 1997,
allocated $22.3 million ($24 million in 1998
and 199917) to enable the National Program
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of Cancer Registries to help states enhance
registries and advance the agenda for a cen-
tralized database of cancer incidence in the
United States. A key player at all levels of this
development process is the North American
Association of Central Cancer Registries,
which, through cooperative agreement and
federal contract, provides guidance, training,
technical assistance, and quality audits.20
Pitfalls in State Cancer Registry
Data
While the expanding population-based
state cancer data hold great promise for can-
cer surveillance, various considerations influ-
ence their validity and usefulness.
Cases vs Persons
Cancer registries record cancer cases,
not patients. Because a patient may have mul-
tiple primary cancers, the same person can
appear more than once in a registry database.
A person with primary cancers in the lung
and breast (or both breasts) is considered as
2 cases; a person with primary cancers in the
tongue, cheek, and palate is considered as
3 oral cancer cases. Because numbers of pa-
tients, rather than numbers of cases, are often
necessary for health care planning and re-
search design, such figures should be rou-
tinely provided, or simple procedures to reli-
ably estimate them from numbers of cases
need to be developed.
Duplicate Reports
When the same cancer is diagnosed and
reported by more than 1 provider (as when a
patient obtains a second opinion), the registry
must consolidate such multiple reports into a
single case record. With information coming
from diverse sources and at different times,
the “unduplication” process is often tedious
and uncertain, because a second report could
represent a recurrence of the original tumor, a
new primary tumor in the same organ, or a
duplicate report of the same case (with the
same or a different diagnosis).
Reporting Delays
Notwithstanding regulations in regard to
timely reporting of new cases, late reports are
received, for diverse reasons. Providers may
not comply with deadlines; institutions may
discover additional cases after sending in
their lists of cases; and unreported cases may
be detected from death certificates. Forward-
ing of reports for residents receiving cancer
care in another state introduces an additional
step. Once received by the registry, each re-
port requires review for potential duplicates.
For these reasons, registry administrators can
find themselves having to repeatedly post-
pone the release of data or make changes in a
data set after it has been released. Both of
these situations are sources of frustration for
investigators as well as registry personnel,
who are committed to accuracy, precision,
consistency, and timeliness.
Race/Ethnicity
Although the inclusion of race/ethnicity
in official databases raises numerous issues,
such information is necessary for research,
monitoring, and policy-making regarding
cancer in populations whose life situations,
culture, and health care experience have dif-
fered greatly from those of the majority pop-
ulation throughout US history.21–26 Compar-
isons across groups can suggest avenues for
research in cancer etiology, prevention, and
outcomes and are required for assessing dis-
parities in care. However, difficulties arise in
coding race/ethnicity, because concepts, per-
ceptions, methodologies, and the populations
themselves change over time.
Because a uniform method of assessing
and coding race/ethnicity does not exist,19
sources of and coding methods for race/eth-
nicity data represent important information
for data users. The method adopted in the US
census is self-identification: the individual
designates his or her own race/ethnicity. By
contrast, race/ethnicity information in med-
ical records usually represents the perception
of physicians, nurses, or clerks. Both pa-
tients’ and providers’ criteria and motivations
for selecting one designation or another vary
across situations.
In the case of some groups, coding is par-
ticularly susceptible to inaccuracy. For exam-
ple, American Indians are frequently classified
as White by health care workers. A recent re-
port from the California Cancer Registry
showed that when its 1988 to 1992 database
was linked with the Indian Health Service
database, 1478 American Indian cancer cases
were identified, 844 (57.1%) of which had
been previously misclassified as non–Ameri-
can Indian cases.27 During its first 3 years of
statewide operation, 41% (1990), 26% (1991),
and 22% (1992) of reports to the North Car-
olina Central Cancer Registry lacked informa-
tion on “Hispanic origin,” which is problem-
atic, especially in analyses of trends.
Cancer Rates
Cancer registry data are primarily used to
estimate cancer incidence rates. These esti-
mates are vulnerable to pitfalls regarding nu-
merators, denominators, and methods of esti-
mation. Changes in numbers of cases, misclas-
sification, and missing data can substantially
distort numerators and, consequently, rates.
For example, correction of the earlier-cited
misclassification of American Indians in Cali-
fornia resulted in an average annual age-
adjusted incidence rate (211.0/100000 for all
sites combined) more than twice the uncor-
rected figure (89.6/100000).27
Likewise, although population counts,
estimates, and projections from the US Bu-
reau of the Census and state agencies gener-
ally provide adequate denominators for esti-
mating rates, undercounts and inaccurate
projections affect rate estimates, particularly
for minority groups.28 The problem of under-
counting inner-city African Americans has
been recognized for years. A different situa-
tion with a similar effect is the inaccuracy in
projections for rapidly increasing popula-
tions, such as Hispanics/Latinos in North
Carolina, Virginia, and other southeastern
states during the 1990s,29 accentuated by the
exclusion of migrant workers and their fami-
lies, predominantly Hispanics/Latinos.30
Even when both numerators and denomina-
tors are accurate, the comparability of age-
standardized cancer rates may be compro-
mised when, owing to the small sizes of
minority populations in many states, stan-
dardization must be carried out via the “indi-
rect” instead of the “direct” method.31,32
The 1994 Gap
The National Program of Cancer Reg-
istries designated 1995 as the year for partici-
pating registries to adopt CDC standards for
data collection and processing. Hence, begin-
ning in 1995, treatment-related data had to be
collected by registries that had never done so,
had to be submitted by a uniform deadline,
and had to meet completeness and quality re-
quirements. In many state registries, achiev-
ing this goal required nearly all available re-
sources. The strategy promoted a great leap
forward toward uniform state cancer inci-
dence databases but had an unfortunate side
effect. To meet national standards for the
1995 data, many registries had to defer pro-
cessing their 1994 data (in some cases, these
data still had not been officially released as of
this writing). The resulting gap interferes
with analyses involving multiple years.
Facilitating Research vs Protecting
Privacy
With the growing use of geographical in-
formation systems, the conflict between confi-
dentiality and data accessibility has become
increasingly problematic. For example, be-
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cause individual-level data on socioeconomic
status (SES) are generally not reported to reg-
istries, investigators have used small-area data
from the US census (median family income,
median educational level) as indicators of
SES. More types of data (e.g., location of
health care facilities, pollution levels, soil
characteristics) can be analyzed through geo-
graphical information systems, and thus the
value of locational data for cases has grown
considerably. Yet, releasing locational data will
often enable identification of individual pa-
tients, thereby compromising confidentiality.
Although the regulations required under
the Cancer Registries Amendment Act guaran-
tee confidentiality of patient information and
access to data for research purposes, the Na-
tional Cancer Institute’s Surveillance, Epi-
demiology, and End Results (SEER) program
and many state registries have been reluctant
to release detailed locational information.
Similarly, when researchers attempt to contact
a patient for interviews or to obtain consent to
examine medical records, their request may be
refused by the patient’s physician or may
prompt hospital registrars to complain to the
state registry.
Rapid Case Reporting
The integration of population-based epi-
demiology and molecular biology provides
new opportunities for cancer etiological stud-
ies but also increases the need for rapid iden-
tification of cases to enable the collection of
blood and tissue specimens promptly after di-
agnosis. However, case reports typically ar-
rive at the registry several months after diag-
nosis. To circumvent this delay, investigators
from the Carolina Breast Cancer Study and
the North Carolina Central Cancer Registry
implemented a rapid case reporting system
for hospitals in the study area that enabled the
identification of newly diagnosed breast can-
cer cases in less than 1 month.33,34 Neverthe-
less, rapid case reporting implies additional
work that some registries are not prepared to
deal with, even when funds are allocated for
extra personnel.
Carcinoma in situ
Carcinoma in situ poses something of a
dilemma for cancer registries. Because, by
definition, carcinoma in situ is not invasive, it
is not classified as a “real” cancer and is
therefore not included in computations of in-
cidence rates (except for bladder cancer,
which has a distinctive transitional epithe-
lium). Although they often collect data on
carcinoma in situ (except for carcinoma in
situ of the cervix), most cancer registries do
not routinely analyze or publish these data.
Because of the high risk of malignant trans-
formation, systematic surveillance of carci-
noma in situ could facilitate studies of the
etiopathogenesis of progression to invasive
cancer and research on prognostic factors.35,36
Also, because in situ lesions represent
an early step in the natural history of cancer,
case–control studies of carcinoma in situ
have advantages in regard to investigating
risk factors that are less detectable with the
passage of time owing to recall problems and
difficulties in obtaining medical records from
the distant past.35 Because the number of
cases of carcinoma in situ is substantial (e.g.,
67255 of the cases [nearly 12%] reported by
the California Cancer Registry from 1988
through 199237), systematic collection, analy-
sis, and reporting of such data can contribute
to cancer control research.35,36
Perspectives
The expansion/enhancement of state
cancer registration supported by the National
Program of Cancer Registries is an impor-
tant step in the development of an infrastruc-
ture for cancer surveillance, prevention/con-
trol, and research. Currently, the main
challenge is to continue nurturing the ongo-
ing process: further expanding to cover all
states, providing training and audits to reach
required standards in each registry, finding
solutions to issues such as those described
here, linking cancer registry databases with
vital statistics (mortality) and administrative
(e.g., Medicare) databases, and periodically
evaluating registry quality through a system-
atic certification process (presently con-
ducted, on a voluntary basis, by the North
American Association of Central Cancer
Registries, with National Program of Cancer
Registries funding). Through these efforts,
the heterogeneously developed registries will
gradually evolve into an efficient, mutually
compatible, nationwide network of popula-
tion-based state cancer registries.
This emerging network should eff i-
ciently complement the existing registries,
especially the SEER program. SEER has col-
lected cancer data for more than 25 years; it
currently covers 14% of the US population
and has recently been linked to Medicare
databases.38 Within the next decade, the state
cancer registry network and SEER together
will collect cancer incidence data on approxi-
mately 97% of the US population,17 laying
the foundation for a national system of can-
cer surveillance.
Availability of more and better data will
lead to greater use of these data, especially
among cancer epidemiology and clinical on-
cology research and training programs and
public health practitioners. Reciprocally, this
data use, nurtured by new scientific knowl-
edge and technological advances, will gener-
ate both demands for additional high-quality
data and the potential for conflict. For exam-
ple, the viability of investigations combining
epidemiologic and molecular data depends on
the ability of investigators to avoid overbur-
dening providers and registries, as well as on
the attitudes toward research of each cancer
registry, hospital, laboratory, and health pro-
fessional involved. Development of mutual
understanding and trust among investigators,
clinicians, and registry personnel is vital.
A key challenge is to balance the needs
of investigators, patients, health care providers,
and registries to simultaneously ensure confi-
dentiality and the scientific usefulness of data.
Research institutions and cancer registries
need to develop regulations better defining the
conditions under which qualified investigators
can gain access to data with the potential to re-
veal identities. Creative solutions to the con-
flict between protecting patients’ privacy and
enabling high-quality health research will
help. In achieving consensus on the need for
public-use data files of national cancer data,
participants in a recent North American Asso-
ciation of Central Cancer Registries workshop
concluded that no one file can meet the needs
of all users, maintain confidentiality, and be
sufficiently flexible to accommodate the wide
range of potential uses. They recommended
the development of 4 separate files covering a
range of user needs and balancing issues of
confidentiality, flexibility, and content.39
An efficient national cancer registry
system is only an intermediate objective; the
ultimate goals are to further understand and
control cancer. Advances in cancer registra-
tion should be coupled with a nationwide ef-
fort to foster the systematic investigation of
cancer patterns and trends by states, regions,
and subpopulations so that, over the next
decade, such information will nurture the de-
sign, implementation, and evaluation of inter-
ventions in each state. Although a national
surveillance system is not mentioned in the
1992 Cancer Registries Amendment Act, the
National Program of Cancer Registries could
proactively collaborate with diverse cancer-
related organizations to jointly analyze data,
help define priorities, suggest prevention/
control interventions, update the research
agenda, and inform policymakers and public
opinion.
Recently, a report by the National Coor-
dinating Council for Cancer Surveillance,
created in 1995 to facilitate collaboration
among organizations interested in cancer sur-
veillance, introduced the notion of a “nation-
ally coordinated system that achieves compa-
rability among current programs while
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remaining relevant, maintaining high quality,
and avoiding extraordinary costs.”40(p1283) It is
through its involvement in such multi-institu-
tional collaborative endeavors that the emerg-
ing network of state cancer registries can play
a critical role as a foundation for cancer sur-
veillance, prevention/control, and research in
the United States.
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